Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir.

Item

http://www.wikidata.org/entity/Q38073204

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Evaluation of dosing and clini ...... n glargine to insulin detemir.

@en

type

Item

label

Evaluation of dosing and clini ...... n glargine to insulin detemir.

@en

prefLabel

Evaluation of dosing and clini ...... n glargine to insulin detemir.

@en

P1476

Evaluation of dosing and clini ...... n glargine to insulin detemir.

@en

P2093

Deanna L McDanel

http://www.w3.org/2001/XMLSchema#string

Erin N Newkirk

http://www.w3.org/2001/XMLSchema#string

Ginelle A Bryant

http://www.w3.org/2001/XMLSchema#string

Karen B Farris

http://www.w3.org/2001/XMLSchema#string

Kathleen E Horner

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

Standards of medical care in diabetes--2012

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.

Refining basal insulin therapy: what have we learned in the age of analogues?

Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised?

Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus.

P304

56-62

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PHAR.1168

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234105615

http://www.w3.org/2001/XMLSchema#string

P698

23307546

http://www.w3.org/2001/XMLSchema#string